$69.49
0.765[1.11%]
At close: Apr 18
$69.49
0[0.00%]
PreMarket: 6:26PM EDT
CVS Health
(NYSE:CVS)CVS Health Stock (NYSE:CVS), Analyst Ratings, Price Targets, Predictions
CVS Health Corp has a consensus price target of $96.54, established from looking at the 94 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Wells Fargo, and Cantor Fitzgerald on April 10, 2024, April 8, 2024, and April 4, 2024. With an average price target of $83.33 between Cantor Fitzgerald, Wells Fargo, and Cantor Fitzgerald, there's an implied 19.92% upside for CVS Health Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Wells Fargo
Piper Sandler
Barclays
Leerink Partners
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CVS Health
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | CVS | Buy Now | CVS Health | $69.49 | 25.2% | Cantor Fitzgerald | Sarah James | → $87 | Reiterates | Overweight → Overweight | Get Alert |
| 04/08/2024 | CVS | Buy Now | CVS Health | $69.49 | 9.37% | Wells Fargo | Stephen Baxter | $83 → $76 | Maintains | Equal-Weight | Get Alert |
| 04/04/2024 | CVS | Buy Now | CVS Health | $69.49 | 25.2% | Cantor Fitzgerald | Sarah James | → $87 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | CVS | Buy Now | CVS Health | $69.49 | 35.27% | Piper Sandler | Jessica Tassan | $93 → $94 | Maintains | Overweight | Get Alert |
| 03/06/2024 | CVS | Buy Now | CVS Health | $69.49 | 12.25% | Barclays | Andrew Mok | → $78 | Initiates | → Equal-Weight | Get Alert |
| 02/26/2024 | CVS | Buy Now | CVS Health | $69.49 | 26.64% | Leerink Partners | Michael Cherny | → $88 | Initiates | → Outperform | Get Alert |
| 02/08/2024 | CVS | Buy Now | CVS Health | $69.49 | 25.2% | Cantor Fitzgerald | Sarah James | → $87 | Reiterates | Overweight → Overweight | Get Alert |
| 02/08/2024 | CVS | Buy Now | CVS Health | $69.49 | 20.88% | RBC Capital | Ben Hendrix | $86 → $84 | Maintains | Outperform | Get Alert |
| 12/22/2023 | CVS | Buy Now | CVS Health | $69.49 | 35.27% | HSBC | Daniela Bretthauer | → $94 | Initiates | → Buy | Get Alert |
| 12/11/2023 | CVS | Buy Now | CVS Health | $69.49 | 42.47% | TD Cowen | Charles Ryhee | $102 → $99 | Maintains | Outperform | Get Alert |
| 11/21/2023 | CVS | Buy Now | CVS Health | $69.49 | 25.2% | Cantor Fitzgerald | Sarah James | → $87 | Reiterates | Overweight → Overweight | Get Alert |
| 11/02/2023 | CVS | Buy Now | CVS Health | $69.49 | 23.76% | Mizuho | Ann Hynes | $88 → $86 | Maintains | Buy | Get Alert |
| 11/02/2023 | CVS | Buy Now | CVS Health | $69.49 | 23.76% | RBC Capital | Ben Hendrix | $91 → $86 | Maintains | Outperform | Get Alert |
| 11/02/2023 | CVS | Buy Now | CVS Health | $69.49 | 43.91% | Morgan Stanley | Erin Wright | $110 → $100 | Maintains | Overweight | Get Alert |
| 09/19/2023 | CVS | Buy Now | CVS Health | $69.49 | 19.44% | Evercore ISI Group | Elizabeth Anderson | $81 → $83 | Upgrade | In-Line → Outperform | Get Alert |
| 09/14/2023 | CVS | Buy Now | CVS Health | $69.49 | 25.2% | Cantor Fitzgerald | Sarah James | → $87 | Reiterates | Overweight → Overweight | Get Alert |
| 09/12/2023 | CVS | Buy Now | CVS Health | $69.49 | 15.12% | Wolfe Research | Justin Lake | → $80 | Upgrade | Peer Perform → Outperform | Get Alert |
| 09/01/2023 | CVS | Buy Now | CVS Health | $69.49 | 18% | Piper Sandler | Jessica Tassan | $85 → $82 | Maintains | Overweight | Get Alert |
| 08/18/2023 | CVS | Buy Now | CVS Health | $69.49 | 30.95% | RBC Capital | Ben Hendrix | → $91 | Reiterates | Outperform → Outperform | Get Alert |
FAQ
What is the target price for CVS Health (CVS)?
The latest price target for CVS Health (NYSE: CVS) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $87.00 expecting CVS to rise to within 12 months (a possible 25.20% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CVS Health (CVS)?
The latest analyst rating for CVS Health (NYSE: CVS) was provided by Cantor Fitzgerald, and CVS Health reiterated their overweight rating.
When was the last upgrade for CVS Health (CVS)?
The last upgrade for CVS Health Corp happened on September 19, 2023 when Evercore ISI Group raised their price target to $83. Evercore ISI Group previously had an in-line for CVS Health Corp.
When was the last downgrade for CVS Health (CVS)?
The last downgrade for CVS Health Corp happened on August 18, 2023 when Edward Jones changed their price target from N/A to N/A for CVS Health Corp.
When is the next analyst rating going to be posted or updated for CVS Health (CVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CVS Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CVS Health was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating CVS Health (CVS) correct?
While ratings are subjective and will change, the latest CVS Health (CVS) rating was a reiterated with a price target of $0.00 to $87.00. The current price CVS Health (CVS) is trading at is $69.49, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.